老年心力衰竭患者B型利钠肽水平与心功能的相关性

目的:探讨老年心力衰竭患者血中B型利钠肽(BNP)水平与心功能分级,左室结构、功能的相关性.方法:入选72例老年心力衰竭患者,并以37例心功能正常的健康老年人作为对照组.以荧光免疫检测法测定各组血BNP水平,应用多普勒超声心动图测定左心室舒张末内径(LVEDD)、左心室射血分数(LVEF),分析血BNP水平与心功能的相...     

心力衰竭患者B型利钠肽的测定与评价

目的:研究B型利钠肽(BNP)在心力衰竭诊断中的应用。方法:采用双抗夹心免疫荧光法检测342例患者的BNP浓度。其中充血性心衰(CHF,心源性)组179例,肺源性心衰组27例,无心衰的对照组136例。结果:(1)在无心衰对照组中,年龄小于55岁组的心源性浓度均值为(35.10±31.93)pg/ml,55～64岁组为(42.85±34.55)pg/ml,65～74岁组为(58.23±25.37)pg/ml,≥75岁组为(60.66±48.95)pg/ml,各组间BNP浓度均值虽随年龄呈上升趋势但无显著差异;(2)对照组中男性BNP浓度为(42.83±38.01)pg/ml,女性为(49.47±48.14)pg/ml,两者无显著差异;(3)在342例患者中BNP以100pg/ml为CHF的判断值时,其敏感性达92.8%,特异性达83.2%,阳性预测值达86.2%,阴性预测值达91.2%;(4)CHF(心源性)患者的BNP浓度均值为(1019.13±972.88)pg/ml,肺源性心衰组为(299.88±275.5)pg/ml,对照组为(45.86±42.89)pg/ml,CHF(心源性)组BNP水平显著高于其他两组,肺源性心衰组又显著高于对照组(P均<0.001)。结论:BNP测定不仅可以作为CHF诊断的一个重要指标,还可用于参考性区分心源性心衰和肺源性心衰,为选择治疗方案提供依据。     

快速测定脑利钠肽预测充血性心力衰竭患者预后的价值

目的　探讨快速测定脑利钠肽预测充血性心力衰竭近期预后的价值。方法　 70例充血性心力衰竭住院患者 ,NYHA心功能Ⅲ级 3 7例、Ⅳ级 3 3例。入院时、出院前或临终前 2 4小时内分别测定血浆BNP ,分析住院治疗前后BNP水平变化与心源性死亡、3 0天内再住院事件的关系。结果　 2 3例患者出现终点事件 (因心功能恶化死亡 6例、再住院 17例 ) ,其入院时BNP水平 ( 15 16pg/ml± 872pg/ml)高于未发生临床终点者 ( 10 3 7pg/ml± 65 4pg/ml) ,P <0 .0 1;发生临床终点者住院期间BNP升高 3 18pg/ml ,而未发生终点事件的患者 ,住院期间BNP平均降低 3 5 9pg/ml ,P <0 .0 1;BNP升高组患者发生临床终点 68.2 % ,BNP降低组患者发生临床终点 16.7% ,P <0 .0 0 5。结论　BNP水平可预测失代偿充血性心力衰竭患者的近期预后     

Correlation between atrial natriuretic peptide and baroreflex sensitivity in patients with congestive heart failure

The aim of this study was to investigate the relationship between baroreflex sensitivity (BRS) and humoral factors in patients with congestive heart failure (CHF). BRS was assessed by the phenylephrine method in 16 patients with CHF and in 13 healthy controls. The CHF group was subdivided into 2 groups according to BRS (group A: <6 ms/mmHg, n=9; group B: > or =6 ms/mmHg, n=7). BRS was markedly depressed in CHF than in the controls (4.8+/-2.0 vs 8.3+/-3.6 ms/mmHg, p<0.01), and lower in group A than group B (3.3+/-1.3 vs 6.7+/-0.6 ms/mmHg, p<0.01). The plasma human atrial natriuretic peptide (h-ANP) level in group A was significantly higher than in group B (54.6+/-27.6 vs 18.0+/-7.4 pg/ml, p<0.01), and a significant inverse correlation was observed between plasma h-ANP and BRS (r=-0.635, p<0.01). However, there were no significant differences between the 2 groups in plasma catecholamine concentration, plasma renin activity and cardiac function by echocardiogram. These findings suggest that the elevation of endogenous ANP may also serve to compensate for impaired BRS in patients with CHF, in addition to its principal actions, such as diuresis and vasodilation.     

心功能不全患者血浆N-末端脑钠肽前体及血清尿酸浓度的相关性

目的：探讨慢性充血性心力衰竭（CHF）患者血浆N-末端脑钠肽前体（NT—proBNP）浓度及血清尿酸（UA）浓度变化及其相关性。方法：65例心功能不全患者,按左室射血分数（LVEF）分两组,即LVEF〉40％组（32例）,LVEF≤40％组（33例）;30例健康体检者作为正常对照组。所有入选者人院后常规检查NT—proBNP,UA,超声心动图测定LVEF。结果：LVEF≤40％组NT—proBNP[1102．3（276．34,1483．3）pg／ml]和UAE478．0（351．5．576．7）μmol／L]水平较LVEF〉40％组[91．5（22．07。165．6）pg／ml;344．7（264．6,424．6）μmol／L]和正常对照组[14．6（5．4,54．1）pg／ml;289．7（214．6,326．3）μmol／L]显著升高．P均〈0．01;LVEF〉40％组NT～proBNP水平显著高于正常对照组（P〈0．01）,UA水平差异无显著性（P〉0．05）;心功能不全患者NT—proBNP与UA呈正相关（r为0．46,P％0．01）;LVEF与NT—proBNP和uA均呈负相关（r=-0．63、-0．42,P均〈0．01）。结论：慢性充血性心力衰竭患者血NT—proBNP浓度和UA浓度升高,且两者呈正相关。测定NT—proBNP和UA浓度有助于判断病情,早期治疗,改善预后。     

慢性心力衰竭患者血红细胞压积与脑钠肽关系的临床观察

目的：探讨慢性心力衰竭患者的血红细胞压积（HCT）与脑钠肽（BNP）的关系。方法：入选在我院心内科治疗的非瓣膜性慢性心衰的患者110例,采用回顾性横断面研究,根据左室射血分数（LVEF）值分成3组：LVEF〈40%组（心衰Ⅰ组,37例）、40%≤LVEF〈50%组（心衰Ⅱ组,34例）和LVEF≥50%组（心衰Ⅲ组,39例）（舒张性心衰）;另选30例LVEF〉50%且无心衰症状的患者作为正常对照组,检测各组HCT和BNP水平,并进行比较分析。结果：与正常对照组患者比较,慢性心衰Ⅲ、Ⅱ、Ⅰ组患者随着LVEF水平降低,HCT[（41.1±2.7）%比（35.4±3.7）%比（32.9±1.5）%比（29.8±4.2）%]水平明显降低（P均〈0.05）,BNP[（182.3±86.8）pg/ml比（652.8±151.3）pg/ml比（874.2±201.8）pg/ml比（1342.2±325.1）pg/ml]水平明显升高（P均〈0.01）;Pearson直线相关分析显示,HCT与BNP呈负相关（R2=0.6716,P〈0.01）。结论：慢性心力衰竭患者血红细胞压积水平与心衰严重程度有关,与脑钠肽呈负相关,血红细胞压积可以作为心衰的预测指标。     

血液B型促尿钠排泄肽检测对充血性心力衰竭的诊断作用

目的　探讨血液 B型促尿钠排泄肽 ( BNP)的检测对充血性心力衰竭的诊断作用。方法　采用美国 ADR公司的 BNP的EL ISA检测试剂 ,对 82例临床诊断充血性心力衰竭进行 BNP检测 ,其中将充血性心力衰竭的患者按 NHYA分级标准分成三个亚级 ( 级、 级、 级 ) ,选择 70例非充血性心力衰竭患者为对照组。结果　实验组与对照组比较 ,血液中 BNP含量分别为 ( 9.78± 1.67) ng/ml和 ( 0 .44± 0 .13 ) ng/ml,实验组明显高于对照组 ,具有极显著性差异 ( P<0 .0 1)。实验组治疗前后对比 ,分别为 ( 9.78± 1.67) ng/ml和 ( 3 .5 6± 0 .14 ) ng/ml,具有极显著性差异 ( P<0 .0 1)。按心功能分级的不同亚组间对比 , 级为 ( 4 .0 5± 0 .67) ng/ml, 级为 ( 7.86± 2 .61) ng/ml, 级为 ( 13 .78± 3 .0 7) ng/m l,含量上差异具有显著性 ( P<0 .0 5 )。结论　检测血液中 BNP的含量可作为诊断充血性心力衰竭的诊断及判断疗效的重要生化指标     

利钠肽与急性心肌梗死后心功能不全和住院病死率相关性研究

目的探讨急性心肌梗死(AMI)患者血浆利钠肽浓度与其急性期心力衰竭和住院病死率之间的相关性。方法选择初发AMI患者294例,其中住院期间存活272例,死亡22例;LVEF≥40%262例,<40%32例;Killip分级Ⅰ级152例,Ⅱ级99例,Ⅲ～Ⅳ级43例。记录发病14～18h血浆利钠肽浓度,发病24～48 h超声心动图检查测定LVEF和左心室二尖瓣舒张早期血流峰值(E)和舒张晚期血流峰值(A)比值(E/A),对各因素间的利钠肽浓度进行比较。结果血浆利钠肽随着Killip分级Ⅰ、Ⅱ、Ⅲ～Ⅳ级逐渐升高,差异有统计学意义(P<0.01)。AMI后急性期心功能Killip分级及肌酸激酶同工酶峰值与利钠肽呈正相关,E/A与利钠肽呈负相关。死亡患者血浆利钠肽明显高于存活患者[(2399.0±1626.0)ng/L vs(480.8±676.0)ng/L,P<0.01]。利钠肽是AMI患者住院死亡的强预测因素(OR=1.259,P=0.028)。结论血浆利钠肽在AMI后的高危患者中明显升高,与急性期心功能Killip分级、舒张功能及死亡均显著相关,可以尝试用于AMI后心功能不全及死亡危险性的早期预后评估。     

心力衰竭患者血清脑利钠肽浓度变化及其意义

目的:探讨充血性心力衰竭(CHF)患者血清脑利钠肽(BNP)浓度变化及其临床意义。方法:选择76例CHF患者(CHF组),32例有呼吸困难的非CHF患者(非CHF组)及30例健康成人(对照组),超声心动图测定左室射血分数(LVEF),酶联免疫吸附法(ELISA)检测血清脑利钠肽(BNP)水平。比较各组血清BNP水平,并动态观察NYHA级、级患者治疗二周后BNP水平变化。结果:(1)心衰组BNP水平(853.6±258.3ng/L)明显高于有呼吸困难的非CHF组(110.1±22.4ng/L)及正常对照组(105.1±21.2ng/L),P<0.01,以113.0ng/L为正常上限值,BNP诊断CHF的灵敏度为100%,特异度为85.5%;(2)NYHA级、级和级的BNP水平分别为615.4±171.0ng/L、837.2±166.1ng/L和1025.7±252.8ng/L,组间比较P<0.01,BNP与左室射血分数呈负相关(r=-0.920,P<0.01);无效者治疗后BNP水平显著高于治疗前。结论:血清脑利钠肽(BNP)浓度有助于心衰的诊断,鉴别诊断和疗效评价。     

心力衰竭病人心房利钠肽与肾素-血管紧张素-醛固酮系统的关系

目的 研究慢性充血性心力衰竭病人心房利钠肽（atrial natriuretic peptide,ANP）与肾素-血管紧张素-醛固酮系统的关系。方法 采用放射免疫分析法测定对受试者血浆血管紧张素Ⅱ（angiotensinⅡ,ATⅡ）、醛固酮（aldosterone,ALD）及ANP含量。结果 心力衰竭组血浆ANP、ATⅡ、AID显著高于对照组,治疗后血浆水平均下降,与治疗前差异有统计学意义（P〈0．001）。ANP水平与ATⅡ水平呈正相关（P〈0．01）,与ALD水平呈正相关、（P〈0．05）。结论 同步监测ATⅡ、ALD、ANP有助于早期发现心力衰竭,判断病情及预后。     

Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide

Background B-natriuretic peptide (BNP), a neurohormone secreted from the cardiac ventricles, reflects left ventricular pressure and correlates to disease severity and prognosis. The fact that BNP levels can now be measured by a rapid assay suggests its potential usefulness in the outpatient clinic. However, if patient activity were to markedly alter BNP levels, its use would be less attractive for monitoring patients in the outpatient clinical setting. Methods A total of 30 patients (10 normal, 10 New York Heart Association [NYHA] class I-II, 10 NYHA class III-IV) exercised with an upright bicycle protocol. Exercise was carried out to 75% of maximum heart rate, and venous blood was sampled before, immediately after, and 1 hour after completion of exercise. Plasma levels of BNP, epinephrine, and norepinephrine were measured. Results BNP levels at baseline were 29 ± 11 pg/mL for normal subjects, 126 ± 26 pg/mL for NYHA I-II subjects, and 1712 ± 356 pg/mL for NYHA III-IV subjects. The change in BNP levels with exercise was significantly lower than the change in epinephrine and norepinephrine (P < .001). In normal subjects, BNP increased from 29 pg/mL to 44 pg/mL with peak exercise, still within the range of normal (<100 pg/mL) . This is compared with larger increases of norepinephrine (716 pg/mL to 1278 pg/mL) and epinephrine (52 pg/mL to 86 pg/mL) with exercise in normal subjects. There were also only small increases in BNP with exercise in patients with congestive heart failure (NYHA I-II, 30%; NYHA III-IV, 18%). For the same groups, epinephrine levels increased by 218% and 312%, respectively, and norepinephrine levels increased by 232% and 163%, respectively. One hour after completion of exercise, there were only minimal changes in BNP levels from baseline state in normal subjects (+0.9%) and patients with NYHA I-II (3.8%). In patients with NYHA III-IV, there was a 15% increase from baseline 1 hour after exercise. Conclusions BNP levels show only minor changes with vigorous exercise, making it unlikely that a normal patient would be classified as having congestive heart failure based on a BNP level obtained after activity. Prior activity should not influence BNP levels in patients with congestive heart failure. Therefore, when a patient presents to clinic with a marked change in their BNP level, it may reflect a real change in their condition. (Am Heart J 2002;143:406-11.)     

充血性心力衰竭患者血浆脑钠素浓度与心功能的关系

目的 :探讨充血性心力衰竭 （CHF）患者血浆脑钠素 （BNP）浓度变化与心功能和 30 d再住院率的关系。方法 :随机选择 CHF患者 78例进行心功能分级 （NYHA分级 ） ,并测定其入院及出院当天血浆 BNP浓度 ,选择 2 0例健康中老年健康体检者作为对照组。结果 :CHF组较对照组血浆 BNP浓度明显升高 ,4 77± 2 4 4 pmol/ L 对 184± 5 4pmol/ L（P<0 .0 1） ;不同心功能分级之间均有显著差异 ,NYHA ～ 级血浆 BNP浓度分别为 2 6 3± 5 6、4 12±16 4、770± 14 2 pm ol/ L（各组间 P<0 .0 1）。 CHF患者 33例出院时血浆 BNP浓度小于 30 0 pmol/ L,30 d再住院率6 % ;4 5例出院时血浆 BNP浓度大于 30 0 pmol/ L,30 d再住院率 2 7% （P<0 .0 5 ）。结论 :血浆 BNP浓度可作为诊断CHF的参考指标 ,随着心衰的加重 ,血浆 BNP浓度逐渐升高 ,当血浆 BNP浓度降至 30 0 pmol/ L 以下时 ,患者 30 d再住院率显著下降。     

Prognostic value of B-type natriuretic peptide in patients with chronic and advanced heart failure

Background: An increase in circulating B‐type natriuretic peptide (BNP) is associated with a poor outcome in patients with acute heart failure. The primary aim of this study was to investigate the prognostic value of BNP levels in patients with chronic and advanced heart failure. Methods: Fifty patients with New York Heart Association functional classes III and IV were enrolled in the study. Their blood BNP levels at admission were measured and patients were on follow up for 12 ± 2 months. Results: There was no significant correlation between BNP levels on admission and left ventricular ejection fraction (r = 0.12, P > 0.05). Twelve patients (24%) died during the follow up. BNP levels were lower in patients who died (501 ± 72 vs 877 ± 89 ng/L, P < 0.01). The logistic stepwise regression analysis showed that lower BNP level (<520 ng/L) on admission was an independent predictor of cardiovascular mortality in these patients (odds ratio 1.21, 95% confidence interval 1.06–2.32, P < 0.01). Conclusion: We conclude that patients with chronic and advanced heart failure have a lower circulating BNP level than those who survive. The paradoxically low BNP level is an adverse prognostic marker in advanced heart failure.     

慢性心力衰竭患者血浆N末端脑钠肽前体浓度与心电图QTc相关性研究

目的 探讨慢性心力衰竭（CHF）患者N末端脑钠肽前体（NT-proBNP）浓度与心电图QTc的关系.方法 选择2012年12月至2013年4月在我院住院的CHF患者90例.根据测定NT-proBNP值的不同将患者分为4组,对组间各项指标进行比较.结果 随着NT-proBNP水平升高,QTc及QTd增大,＞4200 pg/ml组与＜450 pg/ml组相比,QTc及QTd明显增加,差异有统计学意义（P＜0.01）.QTc及QTd与NT-proBNP浓度呈直线正相关（P＜0.01）.结论 随着NT-proBNP浓度升高,CHF患者QTc延长、QTd增加,两者联合可以提高对CHF患者不良预后的预测.     

Diurnal change of plasma atrial natriuretic peptide concentrations in patients with congestive heart failure

Diurnal change of plasma atrial natriuretic peptide (ANP) concentration was observed in 14 patients with congestive heart failure (CHF) and in eight healthy control subjects. Blood pressure, heart rate, and plasma concentration of ANP were obtained at intervals of 4 hours beginning immediately after midnight. In the CHF group, plasma ANP concentrations at the time of blood sampling were all higher than those in the control group. Patients with severe CHF had higher plasma ANP concentrations than those in patients with less severe CHF. Plasma ANP concentration in the control group was highest at 4:00 AM and was lowest at 4:00 PM. The percent change of ANP secretion (% delta ANP): [(ANP at 4:00 AM-ANP at 4:00 PM)/ANP at 4:00 PM] x 100%, increased in the control group, while it decreased in the CHF group. Moreover, % delta ANP was much lower in patients with severe CHF than it was in patients with less severe CHF. There was a possible relation between the severity of CHF and the increase of ANP secretion associated with the relative diminution of nocturnal ANP secretion. Thus the present data imply that the diurnal change in ANP was lost in patients with CHF.